ESR1 and breast cancer: For patients with ER+, HER2− breast cancer, this recommendation is supported by a meta‐analysis demonstrating similar success in achieving breast‐conserving surgery, although lower rates of pCR, with neoadjuvant endocrine therapy vs neoadjuvant chemotherapy.37